CareDx Reports Strong Q3 2024 Revenue Growth
Company Announcements

CareDx Reports Strong Q3 2024 Revenue Growth

CareDx ( (CDNA) ) has provided an announcement.

CareDx, Inc., a leader in precision medicine for transplant patients, has announced its preliminary financial results for Q3 2024, highlighting a strong performance with an expected revenue increase of 23% year-over-year, reaching $82-$83 million. The company saw significant growth in testing services and patient solutions, resulting in a remarkable 16% rise in testing volume. With cash reserves of approximately $240 million and no debt, CareDx is well-positioned for future growth, as it prepares for the official earnings release on November 4, 2024.

For an in-depth examination of CDNA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCareDx price target lowered to $35 from $40 at BTIG
TipRanks Auto-Generated NewsdeskCareDx Inc. Reports Solid Growth and Raises Guidance
TheFlyCareDx reports Q3 EPS 14c, consensus 1c
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App